Date:1/12/2009

pate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the fact that Apo AI is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

'/>"/>

SOURCE SemBioSys Genetics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
2. SemBioSys begins phase I/II trial of insulin produced in plant seeds
3. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
4. SemBioSys announces second quarter 2008 financial and operational results
5. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
6. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
7. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
8. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
9. SemBioSys announces first quarter 2008 financial and operational results
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys initiates toxicology study for safflower-produced insulin